Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATENA: Exemestane vs Observation in Postmenopausal Breast Cancer
NCT00810706Phase 3Terminated
- Sponsor
- Hellenic Breast Surgeons Society
- Start
- Apr 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing observation only with Exemestane (2 arms). Primary endpoint: Disease-Free Survival at 5 years. Started Apr 2001; status: terminated.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00810706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810706.